A High Protein Egg White Pudding for People With Kidney Failure (HiPE KF)
NCT06343727
Recruiting
The goal of this clinical trial is to compare protein supplements in patients with kidney failure on dialysis. The main questions it aims to answer are: * To determine whether the supplementation of egg white protein pudding in a population of individuals with kidney failure on dialysis is feasible. * To determine whether egg white protein pudding supplementation improves serum albumin similar to other standard nutritional supplements. * To determine the effects of the egg white protein pudding... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Seven Oaks General Hospital, Winnipeg, Manitoba +1 locations
Conditions: Kidney Failure, Frailty, Kidney Disease, Chronic
Register for Updates
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
NCT06100744
Recruiting
Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time. PsA that begins before a patient's 16th birthday is called juvenile PsA (jPsA).This study will evaluate how safe risankizumab is for the treatment of psoriatic arthritis and to assess change in disease symptoms. Risankizumab is being studied for the treatment of jPsA and... Read More
Gender:
ALL
Ages:
Between 5 years and 18 years
Trial Updated:
07/30/2025
Locations: Arkansas Children's Hospital /ID# 258776, Little Rock, Arkansas +27 locations
Conditions: Juvenile Psoriatic Arthritis
Register for Updates
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
NCT05552157
Recruiting
The purpose is to evaluate the biomarker effect, safety, and tolerability of investigational study drugs in participants who are known to have an Alzheimer's disease (AD)-causing mutation. Stage 1 will determine if treatment with the study drug prevents or slows the rate of amyloid beta (Aβ) pathological disease accumulation demonstrated by Aβ positron emission tomography (PET) imaging. Stage 2 will evaluate the effect of early Aβ plaque reduction/prevention on disease progression by assessing d... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: University of Alabama in Birmingham, Birmingham, Alabama +34 locations
Conditions: Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Register for Updates
A Registry for People With Lung Cancer
NCT06424327
Recruiting
Participants will complete questionnaires before surgery, between 2 to 4 weeks after surgery, and 6 months after surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Rush University Medical Center (Data collection only), Chicago, Illinois +9 locations
Conditions: Lung Cancer, Lung Cancer Stage I
Register for Updates
Feasibility of Choose to Move Replacement Ready
NCT07069179
Recruiting
Choose to Move (CTM) is a 3-month, choice-based health-promoting program for low active older adults being scaled-up across British Columbia (BC), Canada. Recently, the investigators adapted CTM for the \>14000 people in BC who are on surgical waitlists for total knee replacement or total hip replacement (TKR/THR) for osteoarthritis (OA). The primary goal of this observational study is to learn if the adapted program, Choose to Move Replacement Ready (CTM-RR), is feasible to deliver to people wi... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
07/30/2025
Locations: Active Aging Research Team, Robert H. N. Ho Research Centre, Vancouver, British Columbia
Conditions: Osteoarthritis, Osteoarthritis (OA) of the Knee, Osteoarthritis, Hip, Total Knee Arthroplasty; Total Hip Arthroplasty, Mobility Limitation, Social Isolation or Loneliness, Pain, Implementation Science, Physical Inactivity, Sedentary Behaviors
Register for Updates
National Surveillance and Prevention of Neonatal VAP
NCT07109791
Recruiting
The goal of this observational study is to improve how hospital-acquired lung infections (called ventilator-associated pneumonia, or VAP) are diagnosed, treated and prevented in very low birth weight (VLBW) infants, babies born very early (preterm) or very small who often require respiratory support in hospital's neonatal intensive care units (NICUs). The main questions it aims to answer are: * How often do very-low-birth-weight (VLBW) infants get ventilator-associated pneumonia (VAP) in hospi... Read More
Gender:
ALL
Ages:
24 weeks and below
Trial Updated:
07/30/2025
Locations: Royal Alexandra Hospital, Edmonton, Alberta
Conditions: Ventilator-Associated Pneumonia (VAP), Neonatal, Bronchopulmonary Dysplasia (BPD), Antibiotic-Resistant Organisms (AROs), Health-Care Associated Infection (HAI)
Register for Updates
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
NCT06647498
Recruiting
The purpose of this research study is to test the study drug, referred to as remternetug, to determine its effectiveness for the study treatment of asymptomatic (at risk) Alzheimer disease in individuals with AD-causing mutations. This study will also investigate the effects of remternetug on biomarkers (measures of the disease including brain scans, blood and spinal fluid tests), examine safety data to identify any potential benefits or risks, and examine how well participants can tolerate remt... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: University of Alabama in Birmingham, Birmingham, Alabama +34 locations
Conditions: Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Register for Updates
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
NCT06653153
Recruiting
The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo. Participation could last up to 255 weeks including screening, a double-blind treatment period, and a double-blind observation period. In addition, eligible participants who receive placebo during the double-blind treatment period may choose to extend their study participat... Read More
Gender:
ALL
Ages:
Between 55 years and 80 years
Trial Updated:
07/30/2025
Locations: Parkway Medical Center, Birmingham, Alabama +278 locations
Conditions: Alzheimer's Disease
Register for Updates
Intensive Cancer Screening After Cryptogenic Stroke
NCT05733416
Recruiting
The INCOGNITO Pilot Trial is a single centre pilot prospective randomized open-label blinded endpoint (PROBE) trial to assess the feasibility of a full-scale randomized trial to determine whether an occult cancer screening strategy of FDG PET/CT (F-fluorodeoxyglucose positron emission/computed tomography) in addition to usual care increases the number of occult cancers diagnosed after screening compared to usual care cancer screening alone in patients with cryptogenic stroke.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: The Ottawa Hospital, Ottawa, Ontario
Conditions: Occult Cancer
Register for Updates
A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes
NCT04786262
Recruiting
This study will evaluate the safety, tolerability and efficacy of VX-880 infusion in participants with Type 1 diabetes (T1D) and impaired awareness of hypoglycemia (IAH) and severe hypoglycemia.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/29/2025
Locations: City of Hope, Duarte, California +28 locations
Conditions: Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia
Register for Updates
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
NCT05875168
Recruiting
This study will evaluate the safety, tolerability, and efficacy of DS-3939a in participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Florida Cancer Specialists, Sarasota, Florida +23 locations
Conditions: Advanced Solid Tumor, Metastatic Solid Tumor
Register for Updates
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults
NCT06047444
Recruiting
The purpose of this study is to understand the safety and effectiveness of the study drug, Dysport® when compared with placebo in preventing chronic migraine. A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head, and is often accompanied by feeling or being sick and a sensitivity to bright lights and sound. Chronic migraine is defined as having at least 15 days of headache a month with at least 8 of those days being migraine headache day... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Central Research Associates, Birmingham, Alabama +123 locations
Conditions: Chronic Migraine
Register for Updates